Owkin, AstraZeneca Expand AI Drug Research Collaboration With New 3-Year Agreement

Under the agreement, Owkin will deploy AI agents via its K Pro platform to support AstraZeneca teams in analyzing competitive intelligence, drug targets, clinical trial data, and therapeutic development pathways.

Owkin and AstraZeneca have expanded their collaboration through a new three-year licensing agreement focused on AI-driven pharmaceutical research and drug development decision-making.

Under the agreement, Owkin will deploy AI agents via its K Pro platform to support AstraZeneca teams in analyzing competitive intelligence, drug targets, clinical trial data, and therapeutic development pathways. The tools will be integrated into AstraZeneca’s existing IT systems and research workflows.

The AI agents are designed to process multimodal biomedical data and generate insights to assist in evaluating pharmaceutical assets, clinical programs, and emerging research trends. According to Owkin, the system aims to reduce reliance on manual analysis and deliver faster, data-driven decision support within regulated enterprise environments.

The collaboration builds on previous joint work between the two companies in oncology-focused AI applications, including a pre-screening tool for breast cancer patients with gBRCA mutations presented at the European Society for Medical Oncology (ESMO) Congress.

Owkin said its K Pro platform is built on a multimodal patient data network and AI infrastructure designed for pharmaceutical R&D applications, including target prioritization, biomarker identification, and cohort analysis.

The companies stated that the new AI agents are intended to enable research tasks that traditionally take months to be completed in days, particularly in areas involving complex biological and clinical datasets.

Owkin noted that its AI systems are designed to work with structured and curated biomedical data rather than raw unprocessed inputs, allowing more accurate modeling of patient heterogeneity in clinical research settings.

The expansion reflects a broader trend in the pharmaceutical industry toward adoption of agentic AI systems for research workflows. Similar initiatives across the sector include AI-based platforms for clinical trial monitoring, pathology analysis, and drug development optimization.

Owkin CEO Thomas Clozel has previously emphasized the use of large-scale multimodal patient data networks to improve disease understanding, including research efforts in conditions such as Alzheimer’s disease.

The companies said the goal of the collaboration is to improve productivity in pharmaceutical R&D by enabling faster analysis, improved target discovery, and more efficient clinical decision support through AI-enabled systems.

Stay tuned for more such updates on Digital Health News